Latest News

Thyroid Study Initiated at RMH
30-Aug-2018

Work on expanding the indications for Sienna’s hTERT test has resulted in a new study commencing.. READ MORE

Sienna Appoints Chinese Distributor
07-Aug-2018

GaoYuan In-Vitro Reagents Co. appointed as exclusive distributor for mainland China. China is a .. READ MORE

Placement & Rights Issue to Accelerate Technology Expansion Program
20-Jul-2018

Sienna to raise a total of $5.2 million via a placement and rights issue Merchant Opportu.. READ MORE

Investor Information

Sienna is a public listed company headquartered in Melbourne, Australia. In August 2017, Sienna listed on the Australian Securities Exchange under the ticker symbol SDX. The company is governed by an experienced board and management team. Sienna has benefited from over $5.7M in R&D Tax Incentive refunds and government grant programs, significantly bolstering investor contributions and facilitating the progress and growth to date. READ MORE

 

Research

Sienna’s core activities have historically focused on the clinical translation of biomarkers using novel diagnostic technologies for applications in pathology laboratories. The development of inexpensive, high performing in vitro diagnostic tests is expected to lead to radical changes in the approach to care and assessment of cancer patients – a change welcomed by clinicians and governments.  READ MORE

 

About Sienna

Sienna is a medical technology company focussed on the development and commercialisation of novel IVD (in vitro diagnostic) tests. Sienna manufactures IVD products for pathology laboratories to use in their menu of testing services. Sienna has IVD product registration for their Anti-hTERT Antibody (SCD-A7) in several key markets including the USA, European Union and Australia. READ MORE

Sienna has launched the first ever IVD for detection of telomerase as an adjunct to urine cytology for assisting the diagnosis of bladder cancer.

– CEO, Matthew Hoskin

Contact Sienna

Sienna Cancer Diagnostics

1 Dalmore Drive Scoresby VIC 3179 Australia

Telephone +61 3 8288 2141 Facsimile +61 3 8288 2059